In:
Mycoses, Wiley, Vol. 66, No. 5 ( 2023-05), p. 405-411
Abstract:
Invasive fungal diseases (IFD) are life‐threatening and demand timely and appropriate treatment. Research showed that isavuconazole treatment positively affects clinical outcome and length of hospital stay (LOS). Objectives The aim of this study was to assess the hospital costs of patients diagnosed with IFD and treated with isavuconazole using real‐world data from a German cancer centre. Patients/Methods Data and LOS collected from Jan‐2016 to Jun‐2021 at Department I of Internal Medicine, University Hospital Cologne were retrieved. Case‐related resources consumed during the hospital stay across isavuconazole routes of administration (oral, parenteral, and mixed administration) were identified, quantified, valued and compared via a cost analysis that adopted the healthcare payer perspective. Results In total, 101 cases with isavuconazole treatment were identified (oral: n = 22, 21.8%; parenteral: n = 59, 58.4%; mixed: n = 20, 19.8%). Median total LOS was greater in the mixed group (46.5 days; p = .009). Median ICU LOS and ventilation duration were both longest in the parenteral‐only group (16 days, p = .008; 224 h, p = .003). Invasive aspergillosis was the most frequent isavuconazole indication ( n = 86, 85.2%). Average hospital costs were highest in the mixed group (€ 101,226). The median overall costs of cases treated with isavuconazole was € 52,050. Conclusions Treating IFD is resource intensive, often requires intensive care and implies high rates of in‐hospital mortality. Our study emphasises the high hospital treatment costs and thus the need for reimbursement systems to enable live‐saving costly treatments.
Type of Medium:
Online Resource
ISSN:
0933-7407
,
1439-0507
Language:
English
Publisher:
Wiley
Publication Date:
2023
detail.hit.zdb_id:
2020780-3
Bookmarklink
